| Literature DB >> 31231626 |
Joana Viegas1, Ana Filipa Esteves1, Elsa M Cardoso1,2,3, Fernando A Arosa1,2, Marco Vitale4,5, Luís Taborda-Barata1,6,7.
Abstract
Natural mineral (thermal) waters have been used for centuries as treatment for various diseases. However, the scientific background of such therapeutic action is mostly empiric and based on knowledge acquired over time. Among the various types of natural mineral waters, sulfurous thermal waters (STWs) are the most common type in the center of Portugal. STWs are characterized by high pH, poor mineralization, and the presence of several ions and salts, such as bicarbonate, sodium, fluoride, silica, and carbonate. Furthermore, these waters are indicated as a good option for the treatment of various illnesses, namely respiratory diseases (e.g., allergic rhinitis, asthma, and chronic obstructive pulmonary disease). From the sulfide species present in these waters, hydrogen sulfide (H2S) stands out due to its abundance. In healthy conditions, H2S-related enzymes (e.g., cystathionine β-synthase and cystathionine γ-lyase) are expressed in human lungs, where they have mucolytic, antioxidant, anti-inflammatory, and antibacterial roles, thus contributing to airway epithelium homeostasis. These roles occur mainly through S-sulfhydration, a post-translational modification through which H2S is able to change the activity of several targets, such as ion channels, second messengers, proteins, among others. However, in respiratory diseases the metabolism of H2S is altered, which seems to contribute somehow to the respiratory deterioration. Moreover, H2S has been regarded as a good biomarker of airway dysfunction and severity, and can be measured in serum, sputum, and exhaled air. Hence, in this review we will recapitulate the effects of STWs on lung epithelial-immune crosstalk through the action of its main component, H2S.Entities:
Keywords: S-sulfhydration; allergic rhinitis; asthma; chronic obstructive pulmonary disease; hydrogen sulfide; sulfurous thermal waters
Year: 2019 PMID: 31231626 PMCID: PMC6560203 DOI: 10.3389/fpubh.2019.00128
Source DB: PubMed Journal: Front Public Health ISSN: 2296-2565
Major beneficial effects induced by sulfurous thermal waters.
| Prophylactic | • Preventive role in the progression of inflammatory states or subsequent superinfection | ( |
| Therapeutic | • Nasal resistance and flow amelioration | ( |
| Socio-economic | • Reduction of school and work absenteeism | • Possible in respiratory diseases, but still needs to be addressed in cost-effectiveness studies |
STW inhalation can have either a prophylactic or a therapeutic role, which may be associated with potential socio-economic benefits.
Figure 1Hydrogen sulfide metabolism: synthesis, storage, degradation, and clearance. (A) Both exogenous (diet; sulfurous thermal waters; synthetic compounds, e.g. NaHS) and endogenous (L-cysteine) are the main sources of H2S biosynthesis. (B) H2S is synthesized mainly via CBS and CSE enzymes, although it can also be produced through the combination of CAT and 3-MST. Nevertheless, non-enzymatic sources (e.g., polysulfides, bacterial sources) can also be H2S sources. (C) Subsequently, H2S can either act on its biological targets or (D) be stored as bound sulfane sulfur and acid-labile sulfur pools. (E) In order to maintain H2S levels balanced, this gas undergoes further degradation via oxidation in mitochondria (quinone reductase) or, methylation in the cytoplasm (thiol-S-methyltransferase), or it can be scavenged by binding to hemoglobin. (F) Finally, H2S is excreted by the kidney (urine), intestine (flatus) or lung (exhaled air). CAT, cysteine aminotransferase; CBS, cystathionine β-synthase; CSE, cystathionine γ-lyase; H2S, hydrogen sulfide; HS, hydrosulfide; 3-MST, 3-mercaptopyruvate sulfurtransferase; NaHS, sodium hydrosulfide; S2−, acid-labile sulfur; SSH, hydrodisulfide; STWs, sulfurous thermal waters.
Figure 2Hydrogen sulfide-mediated S-sulfhydration reaction. H2S adds a sulfhydril group to thiol groups of reactive cysteine residues, resulting in sulfhydration of its biological targets. H2S, hydrogen sulfide.
Figure 3Hydrogen sulfide interaction and effects upon the activity of its biological targets. (A) In a physiological concentrations, H2S can either activate or inhibit different ion channels, providing a cytoprotective effect to the cell. (B) By inducing an increment of intracellular calcium, H2S induces the translocation of CSE to the mitochondria, resulting in the generation of H2S. In parallel, the H2S-mediated S-sulfhydration of the mitochondrial alpha subunit of ATP synthase, allows the augmentation of cAMP levels. This results in the increase of mitochondrial ATP production. Moreover, H2S can also inhibit PDE activity, allowing the increase of cAMP and cGMP net levels, thereby conferring vasodilatory and anti-proliferative properties (C) If, on the one hand, H2S seems to be able to prevent MAPK activation, on the other hand it increases the levels of other kinases, including PI3K/Akt, and protein kinase C, some of which can inhibit the production of pro-inflammatory cytokines. (D) The H2S-induced S-sulfhydration of Keap 1 induces the translocation of Nrf2 to the nucleus leading to the expression of ARE, which results in the augmentation of antioxidant responses. Moreover, H2S can induce NF-κB activation or inhibition. This depends upon the stage of underlying inflammation. ARE, antioxidant response elements; , intracellular calcium; CSE, cystathionine γ-lyase; , ATP-activated potassium channels; Keap 1, Kelch-like ECH-associated protein 1; MAPK, mitogen-activated protein kinase; NF-kB, nuclear factor-kappa B; Nrf2, nuclear factor erythroid-related factor 2; PI3K, phosphoinositide 3-kinase; PDE, phosphodiesterase; PKB, protein kinase B; PKC, protein kinase C; SMCs, smooth muscle cells; TGF-β, transforming growth factor-β; SSH, S-sulfhydration; VECs, vascular endothelial cells; the green arrow indicates that the pathway is stimulated and the red arrow indicates that the pathway is inhibited.
General biological effects of hydrogen sulfide at physiological levels in the lungs.
| Mucolytic | Less viscous mucus | Human patients | Chronic inflammatory processes | Sulfur-chloride-bicarbonate-alkaline/- | 12-days 1x daily humid-hot inhalation for 10 min | ( |
| Reduction of mucociliary transport time | Human patients | Chronic sinonasal disease | Sulfurous-arsenical-ferruginous/ISCS | 12-days 1x daily warm vapor followed by nasal aerosol | ( | |
| Chronic rhinosinusitis | Sulfurous/Physiological solution | 12-day 1x daily warm vapor inhalations and nasal irrigations | ( | |||
| Chronic sinonasal inflammation | Radioactive water/- | 14-days 1x daily warm vapor inhalations followed by nasal aerosol for 10 min | ( | |||
| Increment of mucociliary clearance | Hypoxia | Na2S/Hyperoxia (100% O2) | 100 μM Na2S applied to the apical compartment | ( | ||
| Antioxidant | Increment of GSH availability and SOD levels | Inflammatory lung diseases | NaHS/iNOS inhibitor | Treatment 30 min before each OVA challenge during 6 days | ( | |
| Anti-inflammatory | Suppression of leukocyte adherence and migration | Myocardial ischemia-reperfusion injury | Na2S/- | NA2S administered into the left ventricular at the time of reperfusion at different doses | ( | |
| Acute inflammation | NaHS and Na2S/- | ( | ||||
| Inhibition of macrophage inflammation | Macrophage inflammation | NaHS/Hexyl acrylate | Pre-treatment with NaHS for 30 min | ( | ||
| Inhibition of myeloperoxidase activity | Colitis and healthy state | Na2S/- | Interaction of sulfide and MPO assessed using several spectroscopic techniques | ( | ||
| Antiviral/antibacterial | Protective role in controlling viral assembly/release | RSV infection | GYY4137/- | GYY4137 administration performed i.n. at different doses and timing of RSV infection | ( | |
| RSV infection | GYY4137/- | GYY4137 administrated either prior to infection, but not throughout the duration of infection, or at different times p.i. after the viral inoculum was removed | ( | |||
| Inhibition of bacterial biofilm production | Human patients | RURT infection | Sulfurous/physiological solution | 12-day 1x daily warm vapor inhalations | ( | |
| Analgesic | Induction of endogenous opioid system activation | Visceral pain | Na2S/vehicle | 100 μmol/kg Na2S administered 5 min before CRD | ( | |
| Anti-proliferative | Inhibition of SMCs proliferation | – | NaHS or GYY4137/- | 100 μM H2S donors exposure for 2 or 3 days | ( | |
| Anticancer | Increase in the production of metabolic acid lactase of cancer cells | Cancer | NaHS or GYY4137/ZYJ1122 | 400 μM H2S donors exposure for 5 days | ( | |
| Impairment of pH regulatory system of cancer cells | ||||||
A549 cell line, human alveolar type II-like epitelial cell line; CRD, colorectal distension; GYY4137, morpholin-4-ium 4 methoxyphenyl [morpholino] phosphinodithioate, a novel water-soluble, slow releasing H.
Exposure to H.
Dual biological effects of hydrogen sulfide: beneficial vs. deleterious.
| Antioxidant/oxidant | • Increase in GSH availability | ( | • Increase in ROS | ( |
| Anti-inflammatory/inflammatory | • Suppression of leukocyte adherence and migration | ( | • Promotion of granulocyte survival | ( |
| Bioenergetic | • Mitochondrial ATP synthesis | ( | • Induction of mitochondrial cell death pathways | ( |
| Modulation of cancer | • Procarcinogenic | ( | • Anticarcinogenic | ( |
H.
Exposure to low levels of is associated with beneficial effects. In contrast, exposure to higher levels and fast-releasing rate of exposure to H.